TrialCancer immunology, immunotherapy : CII2025

Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study.

Hongchuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.